The objective of this study was to determine risk factors predicting seizures and damage caused by seizures in a multi-ethnic systemic lupus erythematosus cohort (PROFILE) that includes systemic lupus erythematosus patients (n = 1295) from five different US institutions. Only patients with seizures after systemic lupus erythematosus diagnosis (incident) were included in the analyses of clinical seizures (80/1295, 6.2%), but all patients (prevalent and incident) were included in the analyses of damage caused by seizures (51/1295, 3.9%). We examined socioeconomic-demographic, clinical, and genetic variables predictive of clinical seizures and damage from seizures by Cox proportional hazard ratios (HR) and 95% confidence intervals (CI). Independent predictors of a shorter time to the occurrence of clinical seizures were younger age (HR = 1.0; 95% CI 0.9-1.0), having Hispanic-Texan ethnicity (HR = 2.7; 95% CI 1.3-5.7) or African-American ethnicity (HR = 1.8; 95% CI 1.0-3.1), and the previous occurrence of a cerebrovascular accident (HR = 3.3; 95% CI 1.6-7.1) or an episode of psychosis (HR = 2.4; 95% CI 1.1-5.0), whereas the previous occurrence of photosensitivity (HR = 0.5; 95% CI 0.3-0.9) was the only independent predictor of a longer time to the occurrence of clinical seizures. Independent predictors of a shorter time to the occurrence of damage caused by seizures were younger age (HR = 1.0; 95% CI 0.9-1.0), male gender (HR = 2.4; 95% CI 1.1-5.4), and the occurrence of a previous cerebrovascular accident (HR = 2.7; 95% CI 1.0-7.0) or an episode of psychosis (HR = 4.7; 95% CI 2.3-9.9). No allele from the candidate genes examined (HLA-DRB1, HLA-DQB1, FCGR2A, FCGR3A, or FCG3B) predicted clinical seizures or damage caused by seizures. Lupus (2008) 17, 177-184.
Introduction
Systemic lupus erythematosus (SLE) is a prototypic immune complex disease characterized by a variable course and outcome. Neuropsychiatric involvement is often reported, across a wide range of manifestations occurring with variable frequencies across studies. [1] [2] [3] [4] [5] [6] The variability in reporting is also represented when focusing on seizures, where the prevalence reports range from 6% to 51% in adult and pediatric patients. [1] [2] [3] [4] [5] [6] Seizures occur in the setting of active multisystem disease or present as an isolated clinical event. 7 Although antiphospholipid (aPL) antibodies have been associated with seizures, 4, 7, 8 there are likely to be other risk factors for the development of seizures in SLE. Familial aggregation of SLE suggests a genetic component to disease susceptibility, and a number of studies have now defined genetic associations with individual candidate genes. [9] [10] [11] [12] On the basis of our observation that low-affinity Fc receptors for IgG are associated with the development of end-stage renal disease in patients with SLE, 13 we posited that a genetic component may also contribute to seizure risk.
Human familial epilepsy and other Mendelian epilepsy syndromes have defined genetic mutations. 14, 15 Additional evidence suggests that vaccine-related encephalopathy 16 and some seizure disorders might be related to mutations in sodium channel genes. 14 However, in sporadic seizures, there are no clearly defined associated genetic abnormalities including ion channel gene mutations. 14 In this study, we extend our previous reports on a multi-ethnic, multi-center cohort of SLE patients, named PROFILE, 17 to address potential genetic risk factors for seizures. This cohort was constituted in 1998 by combining the existing cohorts at Northwestern University (NU), Johns Hopkins University (JHU), the University of Alabama at Birmingham (UAB), the University of Texas Health Science Center at Houston (UTH), and subsequently the University of Puerto Rico Medical Sciences Campus (UPR) 13, 17 with the overarching hypothesis that the patients' genetic profile might allow for the prediction of their disease phenotype, hence the name PROFILE. Our specific hypothesis for the current study is that seizures might be related to the intensity of the immune complex-mediated inflammatory disease response. Therefore, we tested several candidate genes, previously noted to be associated with renal damage in SLE, for their association with seizure occurrence.
Patients and methods
Institutional review board approval to constitute this cohort and to follow these patients over time was obtained at each participating institution in accordance with the Declaration of Helsinki. As previously described, 17 PROFILE is a multi-institutional (NU, Chicago, IL; JHU, Baltimore, MD; UAB, Birmingham, ALA; UTH, Houston, TX; and UPR, San Juan, PR) cohort of patients with SLE. PROFILE patients are those from the individual cohorts who meet the American College of Rheumatology (ACR) revised and updated classification criteria, 18, 19 are 16 years of age or older, and have disease duration ≤10 years at the time they enter this cohort. They are also of defined ethnicity [Hispanic of Mexican ancestry (residing and enrolled in Texas, hence Texan-Hispanics), Hispanic of Puerto Rican ancestry (residing and enrolled in Puerto Rico, hence Puerto Rican-Hispanics), African-American, and Caucasian], having reported all four grandparents to be of the same ethnic background. In all, 206 patients were from NU, 586 from JHU, 340 from UAB, 189 from UTH, and 102 from UPR. The PROFILE database consists of those variables common to the individual cohorts, which were identified after carefully mapping the different cohorts' databases. 17 The variables for the current analyses include both demographic and socioeconomic elements (age, gender, education, employment, marital status, and smoking) and clinical elements [disease duration; the number of ACR criteria at entry into the cohort (seizure criterion excluded); occurrence of psychosis; cerebrovascular accident and seizure; presence of antiphospholipid syndrome (APS, which includes myocardial infarction, definite or classic angina, procedure for coronary artery disease (bypass graft), cerebrovascular event, claudication for more than 6 months, peripheral arterial thrombosis or peripheral venous thrombosis, but excluding pregnancy events recorded after SLE diagnosis) and aPL antibody positivity; disease damage as assessed by the Systemic Lupus International Collaborating Clinics (SLICC) Damage Index (seizure criterion excluded), and medication intake (hydroxychloroquine, cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil, and glucocorticoids) 20 ]. Comorbidities [diabetes mellitus (intake of oral hypoglycemic agents and/or insulin) and hypertension (recording of three abnormal readings and/or use of antihypertensive medications)] were also noted.
Time of diagnosis was defined as the date when a patient met four ACR classification criteria. Incident seizure involvement was defined when patients met the ACR neurological criterion for seizures and thus attributed to SLE, 19, 21 either at the time of diagnosis or after diagnosis. Prevalent seizure (onset before diagnosis) was excluded from these analyses because disease duration was defined as the time between diagnosis and enrollment into the PROFILE cohort, and the timing for Cox proportional hazards model (see below) could not be calculated if an event occurred before the time of diagnosis. Clinical seizures due to other causes, such as hypertensive seizures, were excluded from the analysis. Damage from seizures was defined when patients met the SLICC Damage Index definition of seizures (persistent seizures for more than 6 months requiring treatment). 22 From the genetic domain, selected HLA-DRB1 (HLA-DRB1*08, HLA-DRB1*0301, HLA-DRB1*150), HLA-DQB1 (HLA-DQB1*0201, HLA-DQB1*0602), FCGR2A, FCGR3A, and FCGR3B alleles were included. Genomic DNA was extracted using the PureGene kit (Gentra Systems, Minneapolis, Minnesota, USA) following the manufacturers' recommendations. HLA-DRB1 and HLA-DQB1 were genotyped as we have previously described. 23, 24 FCGR2A, FCGR3A, and FCGR3B were genotyped as previously described and by Pyrosequencing (Biotage, Charlottesville, Virginia, USA) using gene-specific primers. 25 The distributions of selected FCGR alleles by ethnic group have previously been reported. 13 
Analyses
The common variables from the individual databases were pooled to constitute one single database. 17 Descriptive statistical tests (Chi-square or Fisher's exact test for proportions and Student's t-tests for means) were used to compare variables from the different domains for incident cases of seizure involvement versus non-cases (prevalent cases with onset before diagnosis were excluded).
Model development
Variables with a P < 0.10 in the univariable analysis and those believed to be clinically relevant, regardless of their level of significance (e.g. gender), were entered into the Cox proportional hazards regression models. Hazard ratios (HR) for ethnicity were calculated using Caucasian ethnicity as the referent group. The development of incident seizures was the dependent variable in two models (association and prediction). Similarly, the development of damage caused by seizures was the dependent variable in the other two models (association and prediction). Employment was excluded from the prediction models because change in this variable may result from, rather than predict, the occurrence of seizures. Likewise, medication use was excluded from the prediction models as the precise timing for them was not available. Figure 1 shows the flow of PROFILE patients into the timedependent analyses described.
Results

Seizure involvement
At the time of analyses, 1295 patients constituted the PROFILE cohort and 115 of these had developed seizures ( Figure 1 ). Of these 115 patients, 35 had developed seizure before diagnosis (prevalent cases) and were not included in the analyses presented. The 80 incident cases (those who developed seizures at the time of or after SLE diagnosis) were younger (31.4 vs 36.4 years, P = 0.0006), less likely to be unemployed (39.5% vs 62.0%, P < 0.0001), to be African-American (51.3% vs 34.1%) or Hispanic-Texan (15.0% vs 10.0%), and less likely to be Caucasian (31.3% vs. 47.6%) and Hispanic-Puerto Rican (2.5% vs 8.3% P = 0.0014), to have a greater number of ACR criteria (excluding the seizure criterion) (6.7 vs 5.8, P < 0.0001), to have other neurological manifestations (psychosis [10.0% vs 2.8%, P = 0.0004] and cerebrovascular event [17.5% vs 4.0%, P < 0.0001]), to have more disease damage (excluding the seizure domain) [2.4 vs 1.2, P < 0.0001], to have sustained renal damage requiring dialysis or transplant [22.5% vs 2.6%, P < 0.0001], and to be hypertensive (51.4% vs 36.5%, P = 0.0083) compared with those patients who had not developed seizures. We also explored the relationship of individual ACR non-central nervous system (CNS) criteria items with the occurrence of incident seizures and only renal involvement (55% vs 33%, P < 0.0001), and serositis (62% vs 42%, P = 0.0010) were more common in those with seizures than those without seizures. In contrast, photosensitivity was less common in those with seizures than in those without seizures (45% vs 59%, P = 0.0154). These data are shown in Table 1a . There were no other differences in frequency of the remaining ACR criteria items examined in those with or without seizures (data not shown). The distribution of FCGR alleles was comparable for those patients who had developed and those who had not developed incident seizures. The distribution of HLA alleles was similarly comparable for those patients with and without incident seizures (data not shown). 
Damage definition of seizure involvement
As shown in Figure 1 , 51 patients from a total of 115 patients with seizure involvement (incidence and prevalent cases) met the definition of damage caused by seizures 20 after diagnosis. As shown in Table 1b , patients meeting this definition were younger (31.4 vs 36.4 years, P = 0.0053), less likely to be unemployed (40.8% vs 61.0%, P = 0.0046), likely to have a greater number of ACR criteria (excluding the seizure criterion) (6.7 vs. 5.8, P < 0.0001), likely to have renal damage requiring dialysis or transplant [14.9 % vs 3.4 %, P < 0.0001], and likely to have accrued more damage (excluding the seizure domain item) (3.1 vs 1.2, P < 0.0001) than those who did not have seizure-related damage. Within the different ethnic groups, damage caused by seizures was more likely to occur among the African-Americans than among patients in the other ethnic groups (28 of 51 patients, 55%, P = 0.0127). We also explored the relationship of individual ACR non-CNS criteria items with the occurrence of damage caused by seizures, and only renal involvement (51% vs 34%, P < 0.0001) was more common in those with damage caused by seizures compared with those without damage caused by seizures. There were no other differences in the frequency of the remaining ACR criteria items between those with or without seizures (data not shown). 
Factors associated with the time to occurrence of clinical seizures
Risk factors associated with the time to occurrence of seizures were identified in univariable analysis and were combined with other clinically relevant factors for testing in a multivariable regression model. Events considered risk factors, such as cerebrovascular accident, were only included in the models if they occurred before the seizure date. The risk factor variables identified from the univariable analysis for inclusion in the multivariable analysis were younger age (HR = 1.0; 95% confidence interval (CI) 0.9-1.0), Hispanic-Texan ethnicity (HR = 2.6; 95% CI 1.3-5.1), African-American ethnicity (HR = 2.3; 95% CI 1.4-3.7), shorter disease duration (HR = 0.97; 95% CI 0.9-1.0), higher number of ACR criteria (HR = 1.3; 95% CI 1.1-1.5), the occurrence of serositis as defined by ACR criteria (HR = 1.8; 95% CI 1.2-2.9), the occurrence of renal disease by ACR criteria (HR = 2.1; 95% CI 1.4-3.3), the occurrence of a cerebrovascular accident (HR = 3.9; 95% CI 2.2-6.9), the occurrence of psychosis (HR = 3.3; 95% CI 1.5-6.9), the occurrence of renal damage requiring dialysis or transplant (HR = 3.8; 95% CI 2.3-6.5), the lower occurrence of photosensitivity by ACR criteria (HR = 0.5; 95% CI 0.3-0.8), higher damage accrual (HR = 1.2; 95% CI 1.1-1.3), APS (HR = 2.2; 95% CI 1.3-3.7), and the use of intravenous pulse glucocorticoids (HR = 3.7; 95% CI 2.3-5.7) and cyclophosphamide (HR = 5.3; 95% CI 3.4-8.3). The following variables were not significant: Hispanic-Puerto Rican , the occurrence of hypertension (HR = 1.8; 05% CI 1.0-3.2), the occurrence of renal involvement by ACR criteria (HR = 1.82; 95% CI 1.05-3.17), the occurrence of psychosis (HR = 6.2; 95% CI 3.1-12.9), the occurrence of a cerebrovascular accident (HR = 3.3; 95% CI 1.5-6.9), the occurrence of renal damage requiring dialysis or transplant (HR = 4.1; 95% CI 1.8-9.1), the use of intravenous glucocorticoids (HR = 5.1; 95% CI 2.9-9.2) and cyclophosphamide (HR = 4.0; 95% CI 2.3-6.9). The following variables were not significant: Hispanic-Texan or Hispanic-Puerto Rican ethnicities, employment, education, marital status, smoking, diabetes, any of the genetic polymorphisms tested, and the use of low-dose aspirin, hydroxychloroquine, azathioprine, mycophenolate mofetil, and methotrexate. In the final multivariable analysis, only the following variables were independently associated with a shorter time to occurrence of damage caused by seizures:
younger age (HR = 1.0; 95% CI 0.95-1.0), shorter disease duration (HR = 0.9; 95% CI 0.8-1.0), occurrence of psychosis (HR = 3.9; 95% CI 1.8-8.2), and use of intravenous glucocorticoids (HR = 3.5; 95% CI 1.8-6.9), whereas the remaining variables were not significant.
Factors predicting time to occurrence of clinical seizures
Risk factors predicting time to occurrence of incident seizures were identified in univariable analysis and were combined with other clinically relevant variables such as gender but not with employment and medication variables as previously noted. Events considered risk factors, such as cerebrovascular accident, were only included in the models if they occurred before the seizure date. In the final multivariable analysis, only the following variables were independent predictors of shorter time to occurrence of clinical seizures: younger age (HR = 1.0; 95% CI 0.9-1.0), Hispanic-Texan ethnicity (HR = 2.7; 95% CI 1.3-5.7), African-American ethnicity (HR = 1.8; 95% CI 1.0-3.1), occurrence of a previous cerebrovascular accident (HR = 3.3; 95% CI 1.6-7.1) or previous episode of psychosis (HR = 2.4; 95% CI 1.1-5.0), whereas the previous occurrence of photosensitivity (HR = 0.5; 95% CI 0.3-0.9) predicted a longer time to occurrence of clinical seizures. The remaining variables tested were not significant: gender, Hispanic-Puerto Rican ethnicity, disease duration, ACR criteria or damage accrual indices modified to exclude parameters entered separately into the model such as renal involvement or renal damage, serositis, APS, or hypertension.
Factors predicting time to occurrence of damage caused by seizures
Risk factors predicting the time to occurrence of damage caused by seizure were identified in univariable analysis and were combined with other clinically relevant variables such as gender, but not employment and medication variables as previously noted. Events considered risk factors, such as cerebrovascular accident, were only included in the models if they occurred before the seizure date. In the final multivariable analysis, only the following variables were independent predictors of a shorter time to occurrence of damage caused by seizures: younger age (HR = 1.0; 95% CI 0.9-1.0), male gender (HR = 2.4; 95% CI 1.1-5.4), and occurrence of a previous cerebrovascular event (HR = 2.7; 95% CI 1.0-7.0) or a previous episode of psychosis (HR = 4.7; 95% CI 2.3-9.9). The remaining variables tested were not significant: ethnicity, disease 
Discussion
We have previously documented that renal involvement is more frequent among patients with SLE of African-American and Texan-Hispanic (primarily Mexican) ancestry. 13 In the current study, we show that incident seizures also occur more often in these two ethnic groups and that African-American patients were more likely to have disease damage caused by seizures. In contrast to our findings that showed lowaffinity Fc receptors for IgG (FCGR) involvement when assessing disease damage focusing on the development of end-stage renal disease in patients with SLE, 13 we were unable to show a similar relationship between the development of incident seizure or damage caused by seizures in patients with SLE and candidate gene allelic polymorphisms of HLA-DRB1, HLA-DQB1, FCGR2A, FCGR3A, and FCGR3B. The absence of a genetic association with seizure involvement in our cohort may represent a power issue; given the exploratory nature of our analyses, however, a formal power calculation was not done a priori. Alternatively, it is possible that we did not test for the appropriate candidate gene(s). However, the known genetic associations with epilepsy are rare and usually familial or associated with ion channel gene mutations as described earlier. 14, 15 It is unlikely that we would find these latter abnormalities in SLE, as our approach was to target previously identified candidate genes and their alleles associated with the immune response in SLE.
We also noted that younger age was a significant factor in these analyses as has been noted in previous studies. 5, 8 We and others have observed that shorter disease duration contributes to both seizure occurrence and damage caused by seizures, suggesting that seizures are a relatively early occurring event in the disease course of lupus. 5, 8 We did not note a relationship between education and seizure onset. Nevertheless, given that ethnicity is not merely a biological construct but one that also encompasses ancestry, geography, history, values, culture, and language, the role of socioeconomic factors in the development of seizures or damage caused by seizures should not be easily dismissed. 26 We have confirmed previous findings related to the associations between damage accrual, clinical seizures, or damage caused by seizures, 7 between a previous cerebrovascular accident and clinical seizures, 8 and the observation that male gender may have a role in increasing the risk of damage caused by seizures. 7 In contrast to our study, where a previous episode of psychosis predicted damage caused by seizures, another study showed only a relationship between clinical seizures and psychosis. 7 We were unable to show a relationship between APS and clinical seizure or damage caused by seizures.
Our study has several limitations. First, it includes patients with SLE recruited at academic health centers and thus they may not be representative of the overall lupus population; this may make our data less generalizable than if our patients have been recruited from the community. Second, because different disease activity indices such as the Systemic Lupus Erythematosus Disease Activity Index 27, 28 and the Systemic Lupus Activity Measure-Revised 27,28 had been obtained at the different US centers and could not be pooled, we were unable to assess the relationship of ongoing disease activity with the occurrence of seizures. Third, we were unable to include imaging studies such as magnetic resonance imaging, or autoantibody data such as anti-dsDNA, anti-ribosomal or aPL antibodies at the time of the event because they were neither obtained at the time of seizure occurrence in all patients nor read in a centralized laboratory used by all sites contributing patients to the cohort. Therefore, we could not compare our study with others that have showed a relationship between aPL antibodies or the presence of a lupus anticoagulant with seizures. 4, 7, 8 Fourth, we do not have information on the types of seizures that occurred. Finally, seizure involvement occurred before SLE diagnosis in 35 (3.9%) patients in the combined cohort. Because the time of diagnosis was the onset date that was used as the anchor for the Cox proportional hazards analyses, we were unable to include the prevalent seizures in the model. The occurrence of seizures before diagnosis has been recognized, and the frequency of these early-onset seizures is consistent with previous studies. 6, 8 Despite these limitations, our data are quite relevant to clinicians caring for patients from ethnic minorities, particularly young Hispanics (primarily of Mexican and Central American ancestry) and African-Americans who tend to have a lower socioeconomic status than the Caucasian majority and who have now been shown to have more severe disease with respect to end-stage kidney involvement and seizures. A genetic risk factor has been identified for endstage kidney disease in SLE, 13 but the current study does not support a similar association between the tested genetic polymorphisms and the occurrence of seizures or of damage caused by seizures.
